AAN 2024 | CNM-Au8 improves visual function in MS: insights from the VISIONARY-MS trial

Michael Barnett, MBBS, FRACP, PhD, Royal Prince Alfred Hospital Sydney, Sydney, Australia, discusses the Phase II VISIONARY-MS trial (NCT03536559), investigating the novel therapy CNM-Au8 in patients with multiple sclerosis (MS). CNM-Au8 consists of an oral suspension of gold nanocrystals that penetrate neurons and glial cells to improve cellular energetics. The trial included patients with chronic optic neuropathy and investigated changes to visual function. It found both clinical and paraclinical evidence for remyelination and improvements to axonal functioning, potentially inspiring a future Phase III trial. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.